1,25(oh)2-16-ene-23-yne-d3 profile

Let's break down the name and its significance:

**1,25(OH)2-16-ene-23-yne-d3**

* **1,25(OH)2:** This refers to a molecule with hydroxyl (OH) groups at the 1st and 25th carbon positions. This is a characteristic of **vitamin D3 (cholecalciferol)**.
* **16-ene:** This indicates a double bond (ene) at the 16th carbon position in the molecule.
* **23-yne:** This indicates a triple bond (yne) at the 23rd carbon position.
* **d3:** This means that three hydrogen atoms in the molecule are replaced with deuterium atoms. Deuterium (²H) is a heavy isotope of hydrogen, often used as a tracer in research.

**Putting it together:**

This compound is a specifically modified form of vitamin D3, with a double bond at the 16th carbon, a triple bond at the 23rd carbon, and three deuterium atoms replacing hydrogen atoms.

**Importance in Research:**

This modified vitamin D3 molecule is likely being used for research purposes because:

* **Deuterium Labeling:** The deuterium atoms serve as **tracers**. They can be tracked using techniques like mass spectrometry, allowing researchers to study the metabolism, distribution, and activity of vitamin D3 in biological systems.
* **Altered Activity:** The double and triple bonds may alter the biological activity of vitamin D3. This could be investigated to understand how these structural modifications impact the interactions of vitamin D3 with its receptors and target cells.
* **Therapeutic Potential:** The modified molecule might possess altered pharmacological properties compared to native vitamin D3, potentially leading to new therapeutic applications.

**Specific Research Areas:**

The exact research focus using this compound would depend on the specific project. Here are some possibilities:

* **Vitamin D Metabolism:** Studying how the molecule is processed and broken down by the body.
* **Vitamin D Signaling:** Investigating how the molecule binds to vitamin D receptors and triggers cellular responses.
* **Vitamin D Analogs:** Exploring potential therapeutic applications of this modified vitamin D3 for conditions like osteoporosis, autoimmune diseases, or cancer.

**Important Note:** This is a hypothetical example. Without further context or details about the specific research study, it's impossible to know the exact reason for using this modified vitamin D3.

Ro 23-7553: very potent in inhibiting proliferation & inducing differentiation of myeloid leukemic cells in vitro [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	6438384
CHEMBL ID	284121
SCHEMBL ID	8671319
SCHEMBL ID	15262998
MeSH ID	M0176879

Synonym
LMST03020096
(5z,7e)-(1s,3r)-9,10-seco-5,7,10(19),16-cholestatetraen-23-yne-1,3,25-triol
1alpha,25-dihydroxy-16,17,23,23,24,24-hexadehydrovitamin d3 / 1alpha,25-dihydroxy-16,17,23,23,24,24-hexadehydrocholecalciferol
ilx 23-7553
bxl 353
1,25-dihydroxy-delta(16)-23-yne-vitamin d3
ro 23-7553
1alpha,25-dihydroxy-16ene, 23yne-vitamin d3
9,10-secocholesta-5,7,10(19),16-tetraen-23-yne-1,3,25-triol, (1alpha,3beta,5z,7e)-
1,25-dihydroxy-16-ene-23-yne-vitamin d3
ro-23-7553
ilex 23-7553
1,25(oh)2-16-ene-23-yne-d3
5-{2-[1-((1r)-5-hydroxy-1,5-dimethylhex-3-ynyl)(7as)-7a-methyl(3,5,6,7,3a,7a-hexahydroinden-4-ylidene)]ethylidene}(3s,1r)-4-methylenecyclohexane-1,3-diol & cd4
5-{2-[1-((1r)-5-hydroxy-1,5-dimethylhex-3-ynyl)(7as)-7a-methyl(3,5,6,7,3a,7a-hexahydroinden-4-ylidene)]ethylidene}(3s,1r)-4-methylenecyclohexane-1,3-diol
1,25(oh)2-16-ene-23-yne-d3 & cd4
118694-43-2
(1r,3s,5z)-5-[(2e)-2-[(3as,7as)-1-[(1r)-5-hydroxy-1,5-dimethyl-hex-3-ynyl]-7a-methyl-3a,5,6,7-tetrahydro-3h-inden-4-ylidene]ethylidene]-4-methylene-cyclohexane-1,3-diol
ilex-23-7553
bxl-353
CHEMBL284121
ilx-237553
ilx7553
ilx23-7553
ilx-23-7553
ilx 237553
(1r,3s,5z)-5-[(2e)-2-[(3as,7as)-1-[(2r)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
unii-o13qtc8612
o13qtc8612 ,
ilx 237553 [who-dd]
1,3-cyclohexanediol, 5-((2e)-2-((3as,4e,7as)-3,3a,5,6,7,7a-hexahydro-1-((1r)-5-hydroxy-1,5-dimethyl-3-hexyn-1-yl)-7a-methyl-4h-inden-4-ylidene)ethylidene)-4-methylene-, (1r,3s,5z)-
SCHEMBL8671319
SCHEMBL15262998
ro23-7553
Q27285188
DTXSID701318398

Excerpt	Relevance	Reference
" However, while the incidence of TD in birds dosed with 1,25(OH)2D3 was lower (10%) than in control chicks (55%), RO 23-7553 was ineffective (50%)."	( In vivo and in vitro effect of 1,25-dihydroxyvitamin D3 and 1,25-dihydroxy-16-ene-23-yne-vitamin D3 on the proliferation and differentiation of avian chondrocytes: their role in tibial dyschondroplasia. Farquharson, C; Loveridge, N; Rennie, JS; Whitehead, CC, 1996)	0.29

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	23 (74.19)	18.2507
2000's	7 (22.58)	29.6817
2010's	1 (3.23)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	31 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
pd 98059 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source. 2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.	2.05	1	aromatic amine; monomethoxyflavone	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
thymidine [no description available]	2.4	2	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	2	1	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
ici 164384 ICI 164384: structure given in first source. ICI-164384 : A 3-hydroxy steroid that is 17beta-estradiol substituted by a 11-[butyl(methyl)amino]-11-oxoundecyl group at position 7R. It is a steroidal antioestrogen that inhibits the cell proliferation of breast-carcinoma cell lines.	1.99	1	17beta-hydroxy steroid; 3-hydroxy steroid; tertiary carboxamide	anti-estrogen; antineoplastic agent; estrogen receptor antagonist
tretinoin Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.	2.39	2	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
calcitriol dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes	5.68	31	D3 vitamins; hydroxycalciol; triol	antineoplastic agent; antipsoriatic; bone density conservation agent; calcium channel agonist; calcium channel modulator; hormone; human metabolite; immunomodulator; metabolite; mouse metabolite; nutraceutical
vitamin d 2 Ergocalciferols: Derivatives of ERGOSTEROL formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. They differ from CHOLECALCIFEROL in having a double bond between C22 and C23 and a methyl group at C24.. vitamin D2 : A vitamin D supplement and has been isolated from alfalfa.	2.02	1	hydroxy seco-steroid; seco-ergostane; vitamin D	bone density conservation agent; nutraceutical; plant metabolite; rodenticide
cholecalciferol Cholecalciferol: Derivative of 7-dehydroxycholesterol formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. It differs from ERGOCALCIFEROL in having a single bond between C22 and C23 and lacking a methyl group at C24.. calciol : A hydroxy seco-steroid that is (5Z,7E)-9,10-secocholesta-5,7,10(19)-triene in which the pro-S hydrogen at position 3 has been replaced by a hydroxy group. It is the inactive form of vitamin D3, being hydroxylated in the liver to calcidiol (25-hydroxyvitamin D3), which is then further hydroxylated in the kidney to give calcitriol (1,25-dihydroxyvitamin D3), the active hormone.	2.68	3	D3 vitamins; hydroxy seco-steroid; seco-cholestane; secondary alcohol; steroid hormone	geroprotector; human metabolite
seocalcitol seocalcitol: structure given in first source	1.99	1
phosphorus Phosphorus: A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.	2.02	1	monoatomic phosphorus; nonmetal atom; pnictogen	macronutrient
maxacalcitol maxacalcitol: structure given in first source	2.39	2	organic molecular entity
1,25-dihydroxy-16-ene-vitamin d3 1,25-dihydroxy-16-ene-vitamin D3: structure given in first source	1.99	1
sq-23377 Ionomycin: A divalent calcium ionophore that is widely used as a tool to investigate the role of intracellular calcium in cellular processes.. ionomycin : A very long-chain fatty acid that is docosa-10,16-dienoic acid which is substituted by methyl groups at positions 4, 6, 8, 12, 14, 18 and 20, by hydroxy groups at positions 11, 19 and 21, and by a (2',5-dimethyloctahydro-2,2'-bifuran-5-yl)ethanol group at position 21. An ionophore produced by Streptomyces conglobatus, it is used in research to raise the intracellular level of Ca(2+) and as a research tool to understand Ca(2+) transport across biological membranes.	1.98	1	cyclic ether; enol; polyunsaturated fatty acid; very long-chain fatty acid	calcium ionophore; metabolite
tei 9647 TEI 9647: a 1alpha,25-dihydroxyvitamin D3 antagonist; TEI-9647 is the (23S)-isomer, and TEI-9648 is the (23R)-isomer; structure in first source	2	1	vitamin D
1,25-dihydroxy-24-oxo-16-ene-vitamin d3 [no description available]	2	1	vitamin D
acid phosphatase Acid Phosphatase: An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.2.	2.4	2
calcipotriene calcipotriene: a topical dermatologic for the treatment of moderate plaque psoriasis; structure in first source. calcipotriol hydrate : A hydrate that is the monohydrate form of calcipotriol. It is used in combination with betamethasone dipropionate, a corticosteroid, for the topical treatment of plaque psoriasis in adult patients.	2.38	2	hydrate	antipsoriatic
ro 24-5531 [no description available]	2.39	2
1 alpha,24-dihydroxyvitamin d3 1 alpha,24-dihydroxyvitamin D3: RN refers to (1alpha,3beta,5Z,7E)-isomer; formulated in ointment at a concentration of 4 microg/g, for treatment of mild psoriasis	1.99	1

Condition	Relationship Strength	Studies
Cancer of the Retina [description not available]	2.7	3
Eye Cancer, Retinoblastoma [description not available]	3.1	5
Retinoblastoma A malignant tumor arising from the nuclear layer of the retina that is the most common primary tumor of the eye in children. The tumor tends to occur in early childhood or infancy and may be present at birth. The majority are sporadic, but the condition may be transmitted as an autosomal dominant trait. Histologic features include dense cellularity, small round polygonal cells, and areas of calcification and necrosis. An abnormal pupil reflex (leukokoria); NYSTAGMUS, PATHOLOGIC; STRABISMUS; and visual loss represent common clinical characteristics of this condition. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2104)	3.1	5
Milk-Alkali Syndrome [description not available]	2.69	3
Secondary Hyperparathyroidism [description not available]	7.02	1
Hypercalcemia Abnormally high level of calcium in the blood.	2.69	3
Hyperparathyroidism, Secondary Abnormally elevated PARATHYROID HORMONE secretion as a response to HYPOCALCEMIA. It is caused by chronic KIDNEY FAILURE or other abnormalities in the controls of bone and mineral metabolism, leading to various BONE DISEASES, such as RENAL OSTEODYSTROPHY.	2.02	1
Uremia A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms.	2.4	2
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.69	3
Innate Inflammatory Response [description not available]	2.04	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.04	1
Acute Promyelocytic Leukemia [description not available]	1.98	1
Leukemia, Promyelocytic, Acute An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.	1.98	1
Adenocarcinoma, Basal Cell [description not available]	2.9	4
Cancer of Prostate [description not available]	1.98	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.9	4
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	1.98	1
Breast Cancer [description not available]	2.68	3
Breast Neoplasms Tumors or cancer of the human BREAST.	2.68	3
Deficiency, Vitamin D [description not available]	1.98	1
Vitamin D Deficiency A nutritional condition produced by a deficiency of VITAMIN D in the diet, insufficient production of vitamin D in the skin, inadequate absorption of vitamin D from the diet, or abnormal conversion of vitamin D to its bioactive metabolites. It is manifested clinically as RICKETS in children and OSTEOMALACIA in adults. (From Cecil Textbook of Medicine, 19th ed, p1406)	1.98	1
Bone Loss, Osteoclastic [description not available]	1.98	1
Cancer of Colon [description not available]	2.67	3
Colonic Neoplasms Tumors or cancer of the COLON.	2.67	3
Granulocytic Leukemia [description not available]	1.99	1
Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.	1.99	1
Avian Diseases [description not available]	1.99	1
Chondrodystrophic Myotonia [description not available]	1.99	1
Cancer of Eye [description not available]	1.99	1
Osteogenic Sarcoma [description not available]	2.4	2
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	2.4	2
Carcinoma, Epidermoid [description not available]	2.91	1
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.91	1
Kidney Stones [description not available]	2	1
Kidney Calculi Stones in the KIDNEY, usually formed in the urine-collecting area of the kidney (KIDNEY PELVIS). Their sizes vary and most contains CALCIUM OXALATE.	2	1
Colorectal Cancer [description not available]	2	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2	1
Adenoma, Prostatic [description not available]	2	1
Prostatic Hyperplasia Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.	2	1
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	1.97	1
Granulocytic Leukemia, Chronic [description not available]	1.97	1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.	1.97	1
Experimental Leukemia [description not available]	1.97	1

1,25(oh)2-16-ene-23-yne-d3

Description

Cross-References

Synonyms (36)

Research Excerpts

Dosage Studied

Research

Studies (31)

Study Types